211
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Refractory Multiple MyelomaLast Updated:June 18, 2014Completed
Refractory Multiple Myeloma: 1456 Clinical Trials, Page 22 of 146
Hide Studies Not Open or Pending
212
Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
Condition(s):Multiple MyelomaLast Updated:March 22, 2023Recruiting
213
Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:April 26, 2022Recruiting
214
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple Myeloma, RefractoryLast Updated:November 23, 2021Recruiting
215
FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):DS Stage II Plasma Cell Myeloma; DS Stage III Plasma Cell Myeloma; Refractory Plasma Cell MyelomaLast Updated:March 17, 2015Completed
216
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:November 30, 2022Recruiting
217
Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple MyelomaLast Updated:January 16, 2013Completed
218
A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:May 19, 2014Terminated
219
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:February 16, 2017Terminated
220
Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:September 4, 2015No longer available